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Abstract Current advances in the emerging ﬁeld of
synthetic biology and the improvements in key technolo-
gies promise great impacts, not only on future scientiﬁc
development, but also on the economy. In this paper we
will adopt the triple helix concept for analyzing the early
stages of a new ﬁeld of science and innovation, namely
synthetic biology. Synthetic biology is based on the crea-
tion and assembly of parts in order to create new and more
complex structures and functions. These features of syn-
thetic biology raise questions related to standardization and
intellectual property, but also to security and public per-
ception issues that go beyond the classical biotechnology
discussions. These issues concern all involved actors in the
synthetic biology ﬁeld and affect the interrelationship
between science, industry and policy. Based on the results
of the recently ﬁnished EU FP-6 funded project TESSY
(http://www.tessy-europe.de), the article analyzes these
issues. Additionally, it illustrates the setting of clear
framework conditions for synthetic biology research and
development and the identiﬁcation and deﬁnition of com-
mon goals for the future development of the ﬁeld which
will be needed for efﬁcient science–industry–policy inter-
action. It was shown that it will be crucial to develop
approaches that consider the needs of science and industry,
on the one hand, and comply with the expectations of
society, on the other hand. As synthetic biology is a global
activity, the involvement of national decision-makers in
international initiatives will further stimulate the develop-
ment of the ﬁeld.
Keywords Standardization  Intellectual property rights 
Security  Public involvement  Framework conditions 
Knowledge transfer
Introduction
The importance of efﬁcient interactions between science–
industry and government has been discussed among inno-
vation research scholars for about 15 years. Leydersdorff
and Etzkowitz (1996) coined the term ‘‘triple helix of
university-industry-government relations’’ to describe a
new mode of understanding innovation processes where the
efﬁcient interplay between these three institutions becomes
a main driving force of innovation. According to this
perspective, academia, or more broadly speaking, public
research organizations, industry and government collabo-
rate to create new knowledge, technology, processes and
products which are ﬁnally transmitted to users for ﬁnal
usage or for interim use to produce other goods or services.
An important difference between triple helix innovation
and traditional collaborative processes between academia,
industry, and government is that in the triple helix case all
three institutions are playing fully integrated and overlap-
ping roles. The triple helix framework has developed into a
powerful analytical concept in particular for explaining a
new role of universities in innovation processes. The con-
cept states that universities can play an enhanced role in
innovation in the increasingly knowledge-based societies
(Etzkowitz and Leydesdorff 2000).
In this paper we will adopt the triple helix concept for
analyzing the early stages of a new ﬁeld of science and
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that even at very early stages of emerging disciplines the
interrelation between the three triple helix components
plays an important role for setting the scene for further
development of the ﬁeld. We also argue that adopting the
triple helix concept for emerging technologies already at
very early stages could help to overcome some important
roadblocks for generating triple helix innovation dynamics.
Such roadblocks include
• diverging or even conﬂicting attitudes towards intel-
lectual property (strong interest of industry in protec-
tion versus a culture of free exchange and a strong
interest in publishing among academia);
• differing expectations concerning beneﬁts from collab-
orative projects (basic research activities supporting
gain in academic reputation versus focused applied
approach towards commercial application and expected
ﬁnancial returns);
• different perspectives with respect to time horizons of
activities;
• mainly disciplinary organisation of academic research
due to, e.g., disciplinary oriented career schemes
opposed to interdisciplinary industrial perspective and
experience driven by the need to solving problems
using the best suited mix of disciplines or technologies.
Synthetic biology is based on the creation and assembly
of parts in order to create new and more complex structures
and functions. Although one could argue that also classical
biotechnology and metabolic engineering aimed at creating
something new, synthetic biology adds a new quality to this
approach. Whereas classical biotechnology aimed at
exploiting biological systems, living organisms or parts of
them in order to enlarge the knowledge base, produce
goods or provide services, synthetic biology aims at pro-
viding biological parts and contributing to the de-novo
synthesis of non-natural biological systems for a variety of
applications and/or the understanding of the origin of life.
The modularity of parts and the availability of orthogonal
systems provide a new level of abstraction to bio-engi-
neering. These features of synthetic biology immediately
raise questions related to standardization and intellectual
property. In addition, since new devices that did not exist at
all as such in nature may also exert unforeseen or even
dangerous functions, security and public perception issues
need to be considered. All theses issues concern all
involved actors in the synthetic biology ﬁeld and in par-
ticular the interrelation between science, industry and
policy is addressed. Based on results of a recently ﬁnished
EU FP-6 funded project, TESSY (http://www.tessy-europe.
de), we will discuss these issues from a triple helix
perspective. In addition we will also consider two other
areas which will need efﬁcient science–industry–policy
interaction. Theses are the setting of clear framework
conditions for synthetic biology research and development
and the identiﬁcation and deﬁnition of common goals for
the future development of the ﬁeld.
Issues for science–industry–policy interaction
in synthetic biology
Framework conditions
From the very beginning of synthetic biology research the
community discussed whether the ﬁeld of synthetic biology
is the logical extension of classical genetic engineering or
whether it has completely new features. Deciding in favour
of the one or the other has consequences for the regulatory
framework. Assuming that synthetic biology is a further
development of biotechnology, the regulatory model of
rDNA biotechnology should be appropriate. However, a
recent analysis of the Woodrow Wilson International
Center for Scholars showed that there are indeed new
challenges such as the question of risk assessment. In a
context in which the parent agent (chassis, DNA) is less
obvious, classical risk assessment strategies cannot be
applied any more (Rodemeyer 2009). ‘‘The framing pro-
cess for synthetic biology is now well underway and the
outcome will depend on the thoughtful engagement of all
interested parties’’ (Rodemeyer 2009). Initiatives such as
the Joint Conference of the OECD, the UK Royal Society
and the US National Academies of Science on ‘‘Opportu-
nities and Challenges in the Emerging Field of Synthetic
Biology’’ 9–10 July 2009, Washington DC are supposed to
be a basis for such a dialogue among all stakeholder
groups. The development of an appropriate regulatory
framework for synthetic biology may be considered as a
key task to be accomplished at the interface between sci-
ence, industry and governmental agencies. This also
implies that the regulatory framework for synthetic biology
could be ﬁnally considered as a proof of concept con-
cerning a functional triple helix system.
Standardization
Industry representatives in particular argue that synthetic
biology can only develop its beneﬁts and will ﬁnd its way
intoindustrialresearchanddevelopmentifpartsanddevices
arestandardizedandclearlycharacterized.Accordingtothis
view, the availability of ‘‘off the shelf’’ biological bricks
needs to be supported by structured fact sheets of the spec-
iﬁcity of a biological compound as is already in place for a
number of parts and devices that are collected in the ‘‘Reg-
istry of Standard Biological Parts’’ (http://partsregistry.org/
Main_Page). But standardization has to go beyond physical
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123assembly standards and experimental and measurement
standards.Thoughingeneralscientistsareratherreluctantif
their freedom of research is limited, as may be the case
through standards, synthetic biologists now agree that
standards in reporting, organizing, storing, and sharing
biological parts could facilitate their own work. This could
ﬁnally lead to computer/human readable formats for parts
and visual formats. In Table 1, an overview of currently
discussed topics in standardization for synthetic biology is
given. In this sense standardization could be a facilitator to
establish efﬁcient triple helix alliances.
It seems obvious that standardization cannot be invented
by any (political) institution or organization in a top-down
approach, but has to be developed by the users (academia
and industry) themselves. In the initiative ‘‘Provisional
BioBrick Language’’ (PoBol; http://www.pobol.org), it is
planned to capture the minimal information needed to
describe a BioBrick, while remaining extensible to addi-
tional data and open for interlinking. The project is thought
to involve the scientiﬁc community as is indicated by its
name ‘‘pobol’’ which is also the Welsh word for people.
Therefore, the founders around Raik Gru ¨nberg and Jason
Morrison suggest regular 2 day meetings and portable
software libraries to enable developers to incorporate
capabilities into other software.
Within the TESSY project (http://www.tessy-europe.eu),
a roadmap for the future development of the ﬁeld in Europe
was elaborated, covering not only scientiﬁc and techno-
logical milestones but also considering important frame-
work conditions such as funding, regulation, and public
perception (Gaisser et al. 2009a). One milestone for the
next 8 years will be the development of common standards
in synthetic biology. The roadmap suggests adopting an
approach with four consecutive steps: (1) standards for
reporting until 2010, (2) standards for methods and com-
ponents until 2012, (3) a general standard for all -omics
approaches until 2014 and (4) standards for the underlying
mathematics until 2016. The scope of steps number 3 and 4
is not yet completely clear and can be deﬁned in more
detail once scientiﬁc development in synthetic biology and
the basic standardization of parts and devices is further
advanced. This clearly shows the need for the suggested
bottom-up approach and for intensive interactions among
the scientiﬁc community, industry and national or inter-
national governmental institutions which are responsible
for standardization.
Intellectual property issues
The feature of synthetic biology is to share and reuse
standard biological parts and devices. Traditionally it is
well established among the scientiﬁc community to
exchange vectors, strains and other items on a bilateral
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123basis. For industry, however, sharing items seems to be an
unrealistic position at the present time. As long as the
donor of materials cannot guarantee freedom to operate, it
is assumed that the IP practice of industry is not likely to
change for some time. Additionally, it can be argued that
industry would not contribute to a real system of openness
as there are tendencies to maintain a two-tiered system,
keeping the highly valuable parts locked up. The different
cultures and interests in intellectual property issues
between industry and academia seem to be a strong road-
block towards efﬁcient triple helix alliances.
The new quality in synthetic biology is that this sharing
of parts is mediated via speciﬁc registries such as the
‘‘Standard Registry of Biological Parts’’. However, there
are some hurdles associated with the construction of such a
registry as genes or functional parts are partially already
patented and thus cannot be distributed freely among the
scientiﬁc community. A quick search in the Standard
Registry of Biological Parts showed for example that it
contains entries that are based on the green ﬂuorescent
protein, the TET operator or the T7 promotor. All three
constructs are subject to European or global patents.
Whether the parts in the database actually fall under this
patent protection has to be checked individually. This
simple example indicates a certain lack of knowledge
among scientists of possibly associated patent issues. A
similar situation was recently described in the ﬁeld of
molecular diagnostics, where laboratory directors who used
patented tests had only limited awareness of the actual
legal status of the test or denied the applicability of patents
to gene tests (Gaisser et al. 2009b).
The unclear patent situation creates a feeling of uneas-
iness among scientists, as became evident during the par-
ticipatory roadmapping process in the TESSY project. The
clariﬁcation of the open source status of biological parts
and the international harmonization of IP issues were
assessed to be highly relevant. A clariﬁcation within a short
term perspective was called for.
International organizations already started to deal with
the subject, but currently there seems to be a long way to
go. Until then, IP issues remain to be solved on an indi-
vidual basis according to current law. This implies that
each scientist has to be aware of IP issues. He or she has to
identify possible patent holders of parts by patent search or
through public calls as outlined by Berthold Rutz, patent
ofﬁcer at the European Patent Ofﬁce (personal communi-
cation). The next steps will be to negotiate non-assertion
for research purposes and indicate parts covered by patents
and status (asserted/non-asserted, unknown) in database. It
will be necessary to develop license conditions for newly
generated parts based on patent rights and/or patent pool(s)
for synthetic biology. As detailed knowledge of intellectual
property rights is required, the collaboration of scientists
with well informed technology transfer ofﬁces and the IP
departments of private companies will be required. It may
be also helpful to establish public institutions for support
and information in IP questions, as has been shown in other
areas. Efﬁcient cooperation between science, industry, and
governmental institutions will be necessary.
Security aspects
Security threats, in the sense of the intentional release of
biological agents, play an important role in the discussion
between policy and synthetic biology associated industry.
In particular, the DNA synthesis sector is concerned, since
ordered DNA fragments could also bear the danger of
being misused so that basically a careful screening and
checking of all orders including customers would be
required. Both policy-makers, namely the national Minis-
tries of Foreign Affairs, and the private sector will be asked
to come up with measures and international agreements to
prevent misuse. The security concerns are not new to
synthetic biology. Biotechnology and even microbiology
also had to deal with these concerns of misuse. Against this
background there are scientists who argue that there is no
speciﬁc security risk in synthetic biology. On the other
hand, the DNA synthesis industry is confronted with the
questions of how to deal with potentially harmful DNA
orders or clients from potentially aggressive states.
In a ﬁrst initiative, the International Association of
Synthetic Biology (IASB; http://www.ia-sb.eu) developed
suggestions for technical solutions for biosecurity in syn-
thetic biology. This refers to a comprehensive screening of
ordered DNA fragments and their clients. The IASB
members agreed in their meeting in April 2008 to create a
wiki-style non-public forum to discuss shortcomings and
possible improvements in screening software and to share
technical resources on a non-competitive basis. It was
decided that IASB will cooperate with the Goldman School
of Public Policy in building the infrastructure for a viru-
lence factor database. This resource, the ‘‘Virulence Factor
Information Repository—VIREP’’ will be a web-based,
publicly accessible database containing the annotated
genomes of selected viruses, bacteria and possibly
eukaryotic pathogens. Finally, the Industry Association
decided to closely interact with national and international
decision-makers to support efforts to create international
policies.
This initiative is a ﬁrst step towards achieving an
important milestone outlined in the TESSY roadmap on
regulation that highlighted the need for the development of
clear guidance for research and development until 2009.
Further milestones include a code of conduct until 2011
and the implementation of measures to prevent misuse until
2013.
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123Involvement of the public
Lessons from other emerging ﬁelds such as green bio-
technology showed that transparency regarding goals and
realistic communication of scientiﬁc results are crucial to
create an atmosphere of openness and trust. Although
communication with the public is not a guarantee that the
public will accept all scientiﬁc goals, it is helpful to
identify and shape research priorities (Hampel and Renn
1999). Measures and timing of public involvement are the
subject of intense discussions. As democratic societies
want to ensure that the public can make informed decisions
and engage in the public dialogue on science policy, in-
time information of the public seems to be essential. On the
other hand, there is the risk of communicating unrealistic
promises, thereby raising expectations which will hardly be
met by reality (Balmer and Martin 2008).
A second problem is the size of the targeted groups and
the degree of details. In smaller countries such as Swit-
zerland or Denmark it may be possible to engage com-
prehensively in public dialogues. Bigger countries may
apply Internet-based approaches such as the 1,000 ques-
tions campaign in Germany on bioethics (http://www.1000
fragen.de). In any case there is still a need to develop,
apply and evaluate suitable methods and approaches for
efﬁcient public dialogue schemes.
The TESSY roadmap on synthetic biology also indicates
the need for public involvement. Both ‘‘educational activ-
ities on all levels’’ and ‘‘raise public awareness’’ were
assessed as continuous activities that should start imme-
diately. It is worth mentioning that during the participatory
process within the context of the development of the
TESSY roadmap experts estimated that 5–10% of the
funding budgets for synthetic biology should be dedicated
to ELSA research and accompanying measures.
Deﬁnition of common goals
Judging from some recent international conferences on
synthetic biology, the ﬁeld is still addressing/faced with a
number of basic research questions. On the other hand,
industry has a strong interest in applications either in order
to develop new products or to apply the synthetic biology
approach to their own research and development. In order to
further promote the ﬁeld, it seems essential to intensify the
discussion between stakeholders about joint research
efforts. A prominent example of such joint efforts is the
collaboration of public and private institutions and com-
panies in developing the malaria drug Artemisinin. In fact,
the development of a semi-synthetic artemisinin production
system by the introduction of a number of metabolic gene
clusters in a production strain is described as one of the ﬁrst
examples for the proof of the principle of synthetic biology
though there are scientists who classify this approach still as
metabolic engineering rather than synthetic biology. Part-
ners are the Institute for One World Health, which leads the
product development and the responsibility for directing the
collaborative effort; additionally it leads the project’s public
policy and global access goals; Amyris Biotechnology Inc,
which is responsible for optimizing the microbial strain and
using it in the development of a manufacturing process to
make high quality semisynthetic artemisinin; Sanoﬁ-aven-
tis, which provides fermentation and chemistry process
development expertise, and if technical benchmarks are
achieved, will be responsible for the development of an
industrial manufacturing process for semi-synthetic arte-
misinin and the University of California at Berkeley, which
has utilized synthetic biology to develop a microbial strain
to produce artemisinic acid. The University of California at
Berkeley completed its portion of the development efforts
in December 2007 (source: http://www.artemisininproject.
org/partners). It is worth mentioning that from the triple
helix perspective the Artemisinin example is not a perfect
case since the commercial partners act on a non-proﬁt basis.
However, it shows that especially in emerging technologies
alternative funding models and the support of non-proﬁt-
organizations and foundations may be an essential step
towards paving the way for future industrial uptake of the
technology. In particular it illustrates how the interaction
between triple helix partners generates a strong innovation
dynamics. In Europe we are also observing ﬁrst efforts to
establish such new public–private partnerships. Examples
include the EU funded projects Emergence (http://www.
emergence.ethz.ch) and TARPOL (http://www.sb-tarpol.eu).
Conclusions
In this contribution we discuss a number of important socio-
economic issues related to synthetic biology research which
are directly relevant for the science–industry–policy inter-
face. In order to advance activities related to standardiza-
tion, intellectual property, security, and public perception it
seems crucial to jointly develop approaches which consider
the needs of science and industry, on the one hand, but also
comply with the expectations of society on the other hand.
Such joint efforts will also contribute to creating an atmo-
sphere of openness and dialogue among all stakeholders.
Obviously, the role of governmental institutions or more
generally the role of policy could be to act as a moderator in
the dialogue between science and industry. In addition, an
important policy task already in these very early stages
would be to support activities aiming at communicating
synthetic biology research issues to the public. Results of
TESSY research where the scientiﬁc community called for
signiﬁcant public funding of ELSA research related to
synthetic biology strongly support this policy task.
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123Synthetic biology is a global activity. Accordingly,
national efforts related to standards, intellectual property or
security issues are not sufﬁcient and need to be comple-
mented by international initiatives. This means that
national decision-makers need to engage in respective
international activities. Recent examples include interna-
tional working groups such as the OECD Synthetic Biology
Steering Group or the Knowledge-based Bio-Economy
(KBBE-NET) Collaborative Working Group on synthetic
biology.
Until now there have been only a few highlight projects
such as the production of the malaria drug Artemisinin
which demonstrate the potential of the synthetic biology
approach. However, this example illustrates that efﬁcient
collaboration between science and industry is a key to
success. It seems crucial that science and industry collab-
orate to provide proof of the principle of the synthetic
biology approach. An obvious role for policy would be to
facilitate and to support such new public private partner-
ships. Thereby the strong dynamics of triple helix type
innovation could be utilized, already in early stages of the
new ﬁeld of synthetic biology and could exert a signiﬁcant
push to advancing the ﬁeld.
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